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Protocol
AbstrACt
Introduction It has been estimated that a 10%–25% 
reduction in seven key risk factors could potentially 
prevent 1.1–3.0 million Alzheimer’s disease cases 
globally. In addition, as dementia is preceded by more 
subtle cognitive deficits which have substantial social 
and economic impact, effective preventative interventions 
would likely have more extensive benefits. The current 
study evaluates in primary care a multidomain risk-
reduction intervention targeting adults with high risk of 
developing dementia.
Methods and analysis A randomised controlled trial 
(RCT) is being conducted to evaluate three intervention 
programmes using a pragmatic approach suitable to the 
clinic: (1) a 12-week online and face-to-face dementia 
risk-reduction intervention (Body Brain Life—General 
Practice (BBL-GP)); (2) a 6-week face-to-face group 
lifestyle modification programme (LMP); and (3) a 12-
week email-only programme providing general health 
information. We aim to recruit 240 participants, aged 
18 and over, to undergo a comprehensive cognitive 
and physical assessment at baseline and follow-ups 
(postintervention, 18, 36 and 62 weeks). The primary 
outcome is dementia risk measured with the modified 
version of the Australian National University—Alzheimer’s 
Disease Risk Index Short Form. Secondary outcomes 
are cognitive function measured with Trails A and B, and 
the Digit Symbol Modalities Test; physical activity with 
moderate-vigorous physical activity and the International 
Physical Activity Questionnaire; depression with the Centre 
for Epidemiological Studies Depression; cost evaluation 
with the 12-item Short Form Health Survey, Framingham 
Coronary Heart Disease Risk Score and Australian Type 
2 Diabetes Risk Assessment Tool; diet quality with the 
Australian Recommended Food Score; and sleep quality 
with the Pittsburgh Sleep Quality Index.
Ethics and dissemination This RCT is a novel pragmatic 
intervention applied in a primary care setting to reduce the 
dementia risk exposure in adults at high risk. If successful, 
BBL-GP and LMP will provide a versatile, evidence-
based package that can be easily and quickly rolled out 
to other primary care settings and which can be scaled 
up at relatively low cost compared with other strategies 
involving intensive interventions.
trial registration number ACTRN12616000868482
IntroduCtIon
No cure is available for Alzheimer’s disease 
(AD) and other types of dementia. However, 
it is estimated that an achievable 10%–25% 
reduction in seven key risk factors could 
prevent 1.1–3.0 million AD cases internation-
ally.1 It is also estimated that if each of the 
seven risk factors was to be reduced by 5%, 
10%, 15% and 20% per decade, dementia 
prevalence would be reduced by between 
1.6% and 7.2% in 2020, 3.3% and 14.9% in 
2030, 4.9% and 22.8% in 2040 and 6.6% and 
30.7% in 2050.2 Furthermore, as dementia 
is preceded by more subtle cognitive deficits 
strengths and limitations of this study
 ► Body Brain Life—General Practice Programme has 
been built on our dementia prevention research pro-
gramme which has been shown to reduce cognitive 
decline in older adults at risk of dementia.
 ► This pragmatic trial evaluates a multidomain risk-re-
duction intervention in primary care targeting adults 
at increased risk of developing dementia.
 ► A naturalistic approach ensures the programme 
can be adapted efficiently in primary care settings 
if proven effective.
 ► We are aware that most of our outcomes are self-re-
ported and therefore can be subjective. Accordingly, 
we will interpret data conservatively.
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which have substantial social and economic impacts, 
effective preventative interventions would likely have 
additional benefits.
Increasingly and to afford a greater chance of 
producing detectable changes during study timeframes, 
the dementia research community has focused on multi-
domain interventions that address multiple risk factors 
simultaneously.3 Among individuals with high risk factor 
burden, cognitive decline can be reduced (and possibly 
reversed) as a result of cardiovascular risk reduction and 
increase in activities that stimulate and protect the brain 
including cognitive, social and physical activity (PA) and 
an appropriate diet.4 AD and cardiovascular disease share 
cardiometabolic and lifestyle risk factors and cardiovas-
cular risk reduction can be achieved by smoking cessa-
tion, increasing physical activities, adopting a healthy 
diet, reducing abnormally high blood pressure and 
cholesterol in mid-life, and managing major depression, 
overweight/obesity in mid-life and diabetes if present.5 
Altogether, the literature supports the view that multi-
domain interventions aimed at reducing cardiometabolic 
risk and promoting behaviours shown to protect against 
dementia will contribute to preventing cognitive decline, 
reduce overall risk of AD and lower depressive symptoms.
Insufficient PA is the risk factor with the most evidence 
to support its role as a treatment for mild cognitive impair-
ment6 and more generally cognitive decline.7 PA has also 
been shown in randomised controlled trials (RCTs) to 
benefit several other risk factors for dementia including 
depression,8 and cardiovascular risk factors.9 PA modifies 
multiple risk factors and it has direct benefits for brain 
health and cognition.
To bring about risk reduction, there needs to be long-
lasting behavioural change in multiple areas. Achieving 
this requires using techniques such as goal setting, 
decreasing barriers to change, improving self-moni-
toring, having access to information and maintaining 
motivation.10 11 Therefore, this RCT investigates whether 
Lifestyle Management Programmes that offer health-pro-
moting information and practical behaviour change tech-
niques that can be implemented in daily life can reduce 
dementia risk.
recruitment in general practice setting
Primary care is an ideal setting for the implementation 
of the current programme because it is where adults with 
high risk of developing dementia are identified and early 
intervention and treatment are provided.12 Assessment of 
cardiovascular risk factors is common in primary care, as 
is advice about PA and diet. General practitioners (GP) 
commonly screen for diabetes and increasingly identify 
depression. GPs are often the first point of contact for 
patients who are worried that they may have dementia.13
Although there has been one study conducted in 
primary care setting with elderly participants (70–78 years 
old) addressing cardiovascular risk factors,14 the current 
programme is the first of its kind to provide interventions 
to adults (18 years and above) at the primary care setting, 
addressing both cardiovascular and lifestyle risk factors of 
dementia.
MEthods And AnAlysIs
study setting and design
This project is a 6–12 weeks, pragmatic single-blind 
RCT that is designed to assist participants develop and 
maintain a healthy lifestyle, as well as manage chronic 
diseases. The study evaluates the implementation of an 
evidence-based dementia risk-reduction programme that 
we developed and have evaluated previously on volun-
teers15 and which has now been adapted for primary care 
(Body Brain Life—General Practice (BBL-GP)). The 
primary care setting in which the study is held already 
conducted a Lifestyle Modification Programme (LMP) 
aimed at helping to manage chronic disease and main-
taining a healthy lifestyle. The LMP was initially devel-
oped to consist of 12 sessions over 12 weeks. However, its 
format was changed prior to this trial to have 12 sessions 
over 6 weeks. This decision was made by the clinic which 
provides this programme in order for the programme to 
be offered four times a year. The current LMP was chosen 
as a comparison condition for feasibility and to enable 
evaluation of an existing programme for dementia and 
cardiovascular risk reduction. The efficacy of the existing 
LMP had not previously been evaluated.
The existing LMP included 6 weeks of face-to-face group 
education sessions. The BBL-GP Programme included 12 
weeks of individually tailored online education sessions 
with 1-hour face-to-face individual sessions with a dietitian 
and an exercise physiologist. The BBL-GP and LMP are 
being compared with an active control group receiving 
weekly email with links to health information. The study 
is being conducted in Canberra, Australian Capital 
Territory, Australia. The trial has been designed and is 
conducted according to the Consolidated Standards of 
Reporting Trials statements for non-pharmaceutical16 
and pragmatic17 trials and is reported according to the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials guidelines.18
Participants
Participants are being recruited from the National Health 
Co-op (NHC), the largest bulk billing general prac-
tice organisation in Canberra comprising eight clinics. 
Bulk billing is a payment option where the doctor bills 
directly the universal health insurance system (Medi-
care) in Australia for a medical service that the patients 
receive. Invitation emails have been sent to all members 
excluding members who are inactive (those who did not 
renew their memberships), those aged less than 18 years 
or without email addresses. Posters at the clinics are also 
being used for the recruitment. Potential participants 
who express their interest by contacting the LMP coor-
dinator at the NHC or registering on the NHC’s website 
are assessed against the inclusion and exclusion criteria. 
These are the types of adults who a GP would refer to a 
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dementia risk-reduction trial in ‘real life’ and on whom 
we are aiming to evaluate our intervention in a natu-
ralistic context. In addition, risk factors for dementia 
exert their influence over decades and thus the earlier 
one decreases their risk exposure, the more impact it is 
likely to have over their lifespan. Therefore, this interven-
tion programme is open to anyone aged 18 and older. If 
criteria are met, information sheets and consent forms 
are sent to potential participants. On return of consent 
forms via email, each participant is officially registered to 
the study and allocated a unique identity number as well 
as an online account. Recruitment began in July 2016 for 
the duration of 13 months.
Inclusion criteria
A naturalistic approach is used in recruitment and the 
study inclusion criteria being used for this study are those 
already used by the NHC to refer patients to the LMP 
(prior to this research project). The inclusion criteria are 
pragmatic as the practice already had criteria for referral 
to their LMP and in developing the protocol, it became 
clear that introducing a second set of inclusion criteria 
would make implementation difficult and reduce partici-
pant numbers. We therefore decided to use the principle 
that if a GP would refer the patient to the LMP, then they 
would be eligible for the trial. This is a pragmatic feature 
of the current trial that significantly differs from our orig-
inal BBL trial. We aimed to optimise the seamlessness of 
the intervention in primary care and use existing referral 
pathways to increase the probability that the interven-
tion is conducted in a manner that could lead to imple-
mentation in real life. Participants must be aged 18 years 
and over, reside in the Australian Capital Territory, be 
current financial members of the NHC, have access to a 
computer and internet connection at home, be fluent in 
English, Australian permanent residents or citizens (for 
bulk billing eligibility) and must be the only person in 
their household who is taking part in this study to prevent 
being randomly assigned to different groups and sharing 
information about their interventions with each other 
received. To be eligible for the study, participants are also 
required to have a chronic health condition (high blood 
pressure, heart disease, type 2 diabetes or ‘prediabetes’, 
osteoporosis, osteoarthritis, polycystic ovary syndrome, 
kidney or liver disease and depression/anxiety) or be 
overweight or obese (body mass index>25). They are 
also required to agree to commit 1–2 hours a week to 
complete the programme and be interested in obtaining 
advice on improving their lifestyle to reduce the risk of or 
better manage chronic disease. Participants are required 
to complete online assessments and attend NHC at base-
line and 18, 36 and 62 weeks after the commencement of 
the intervention for medical and cognitive assessments.
Exclusion criteria
Participants are not eligible to enrol in the trial if they 
have significant and unstable medical and psychiatric 
conditions that would prevent participation in the trial. 
They are also ineligible if they have sensory deficits or 
mobility limitations that would prevent or substantially 
restrict the delivery of the assessment or intervention, 
have cognitive impairment or are pregnant. Those who 
have previously participated in the LMP were excluded 
from participation. However, those who may be/have 
been participating in other trials, unknown to authors, 
were not excluded.
sample size calculations
Sample size calculations were estimated using G*Power 
(V.3.1.9.2; http://www. gpower. hhu. de/ en. html) and 
have been based on medium effect size as observed in 
the previous Body Brain Life (BBL) project with the same 
primary outcome.15 To detect a medium effect (0.5 SD) 
in a 3-group design (1:1:1), four measurements with a 5% 
risk of type 1 error (α) and 80% power, a total sample size 
of 159 persons is required. To account for a 33% attrition 
(based on previous Lifestyle Modification Programme by 
NHC using the same inclusion and exclusion criteria and 
targeting the same age group), a baseline sample of 240 
is being recruited (80 in BBL-GP group, 80 in LMP group 
and 80 in control group).
Assessments
Participants who meet all inclusion and no exclusion 
criteria are invited to complete online surveys and visit 
NHC for the baseline evaluation, and for weeks 18, 36 
and 62 follow-ups. Immediate follow-up is also conducted 
online at week 7 for LMP, and week 13 for BBL-GP and 
control groups. Table 1 summarises the assessment 
measures and schedule.
screening measures and covariate
In addition to the above inclusion and exclusion criteria, 
further screening measures are conducted to ensure that 
participants are capable of taking part in the study. The 
Adult Pre-exercise Screening System (APSS)19 is used at 
the baseline assessment to identify individuals with acute-
risk/high-risk conditions, or who may be at higher risk of 
an adverse event during exercise. To screen for any cogni-
tive impairment (<25), the Mini-Mental State Examina-
tion20 is administered to participants aged 60 and older.
Health efficacy and motivation for healthiness subscales 
from the Multidimensional Health Questionnaire21 are 
used to measure the extent to which people believe they 
have the ability, capability, skills and talents to take care of 
their own physical health, and to measure people’s moti-
vation to keep in good physical health.
Primary outcome
The primary outcome is one’s exposure profile to demon-
strated risk factors for AD. It is measured with a modified 
version of the Australian National University Alzheimer’s 
Disease Risk Index—Short form (ANU-ADRI-SF).22 The 
ANU-ADRI-SF comprises validated scales assessing 15 indi-
vidual risk and protective factors for AD and dementia. 
Intraclass correlation coefficients suggested that the reli-
ability of the ANU-ADRI-SF compared with the original 
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ANU-ADRI was moderate to strong (0.77–0.99) and statis-
tically significant (p<0.001) except for cognitive activity. 
Therefore, for the assessment of engagement in cognitive 
activities levels only, items from the original ANU-ADRI23 24 
are used in place of those from the ANU-ADRI-SF due to 
limitations of the latter.
secondary outcomes
Secondary outcomes include cognitive function, PA level, 
depressive symptoms, cost of interventions, diet and 
sleep quality. They are measured as follows: cognitive 
function is assessed with processing speed, task switching 
and executive function using Trails A and B, and the 
Digit Symbol Modalities Test (DSMT). These tests were 
chosen because the executive function is the most sensi-
tive cognitive domain to PA interventions25 and a decline 
in processing speed is associated with cardiovascular risk 
factors.26 Both Trails and DSMT have been used widely 
and have been reported to have good reliability and 
validity.27–30 Moderate–vigorous physical activity (MVPA) 
is a continuous measure of activity that registers three or 
more metabolic equivalents for 10 min or longer on an 
ActiGraph Link activity monitor (http:// actigraphcorp. 
com/ products/ actigraph- link/), which is worn for 7 days. 
Self-reported PA is also being recorded using the short 
form of the International Physical Activity Questionnaire 
(IPAQ),31 which is part of the ANU-ADRI-SF. Reliability 
and validity of IPAQ have been tested and confirmed 
across 12 countries.31 Depression is being assessed with the 
Centre for Epidemiological Studies Depression (CES-D) 
Scale,32 which is also part of the ANU-ADRI. CES-D Scale 
has a very high internal consistency and validity.32
Health outcomes are assessed with the 12-item Short 
Form (SF-12) Health Survey,33 Framingham Coronary 
Heart Disease (CHD) Risk Score34 and Australian Type 2 
Diabetes Risk Assessment Tool (AUSDRISK)35 to enable 
cost-effectiveness evaluation of the two health promo-
tion interventions. SF-12 measures both physical and 
mental health status and has acceptable validity and reli-
ability.36 37 Framingham CHD is a validated tool to assess 
cardiovascular diseases38 and AUSDRISK is a diabetes 
Table 1 Assessment measures at the baseline and follow-up evaluations
Assessment measure Baseline
Immediate follow-up (week 7 for 
LMP and week 13 for BBL-GP 
and active control group) Week 18 Week 36 Week 62
Screening
  APSS √
  MMSE (if 60+) √
Questionnaires
  ANU-ADRI √ √ √ √ √
  PSQI √ √ √ √ √
  ARFS √ √ √ √ √
  SF-12 √ √ √ √ √
  MHQ √
Cognitive measures
  Trails A+B √ √ √ √
  DSMT √ √ √ √
Physical and medical evaluation (by 
doctors and nurses)
  MVPA √ √ √ √
  Blood pressure √ √ √ √
  Height, cm √
  Weight, kg √ √ √ √
  Waist and hip, cm √ √ √ √
  Body composition √ √ √ √
  Framingham CHD √ √ √ √
  AUSDRISK √ √ √ √
ANU-ADRI, Australian National University—Alzheimer’s Disease Risk Index; APSS, Adults Pre-exercise Screening System; ARFS, Australian 
Recommended Food Score; AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool; BBL-GP, Body Brain Life—General Practice; 
DSMT, Digit Symbol Modalities Test; Framingham CHD, Framingham Coronary Heart Disease Risk Score; LMP, Lifestyle Modification 
Programme; MHQ, Multidimensional Health Questionnaire; MMSE, Mini-Mental State Examination; MVPA, Moderate–vigorous physical 
activity; PSQI, Pittsburgh Sleep Quality Index; SF-12, 12-item Short Form Health Survey.
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risk assessment tool based on demographic, lifestyle and 
simple anthropometric measures.35
Dietary quality is assessed with a food-based diet 
quality index, the Australian Recommended Food Score 
(ARFS).39 The ARFS is aligned with Australian Dietary 
Guidelines40 and the Australian Guide to Healthy 
Eating41 recommendations. The ARFS total ranges from 
0 to 73 and includes eight subscales: vegetables (0–21), 
fruit (0–12), protein (0–7), vegetarian alternatives (0–6), 
grains (0–13), dairy (0–11), water (0–1), sauces and 
condiments (0–2). Higher scores indicate greater compli-
ance with the Australian Dietary Guidelines and there-
fore better diet quality. The ARFS has demonstrated good 
validity and reproducibility.39
Lastly, the Pittsburgh Sleep Quality Index (PSQI)42 is 
an effective instrument used to measure the quality and 
patterns of sleep in adults. It differentiates ‘poor’ from 
‘good’ sleep quality by measuring seven areas (compo-
nents): subjective sleep quality, sleep latency, sleep dura-
tion, habitual sleep efficiency, sleep disturbances, use 
of sleeping medications and daytime dysfunction over 
the last month. PSQI reports great test–retest reliability 
(0.87) and high correlations with sleep log data.43
randomisation
On completion of the baseline assessment, participants 
are randomly allocated into one of the three groups 
(see table 2 and figure 1). The allocation sequence is 
computer generated by an independent researcher and 
is not known to the study team at the time of enrolment 
and baseline assessment. A permuted block randomisa-
tion sequence comprising block sizes of six stratified by 
gender and age group (18–49 vs 50+) is used. The project 
manager who is not involved with conducting assess-
ments assigns the participants into groups according to 
the generated sequence and notifies participants of their 
group allocation via email.
Interventions
Group 1: BBL-GP
BBL-GP is an intervention package that builds on our 
dementia prevention research programmes. This includes 
Table 2 Comparison of intervention programmes
LMP BBL-GP Active control
Previously applied: Yes, in primary care. 
Evaluation has not been 
carried out.
Yes, with member of general public 
with concern about developing 
dementia. Never been tested in 
primary care setting.
Yes, with member of general public 
with concern about developing 
dementia.
Duration 6 weeks 12 weeks 12 weeks
Frequency Weekly Weekly Weekly
Number of sessions 12 sessions (two sessions 
per week)
Eight online sessions, one session 
with dietitian, one session with 
exercise physiologist
12 emails containing links to various 
websites providing information on 
lifestyle risk factors and disease 
management
Format Face-to-face group 
sessions
1-hour individual session with 
dietitian, 1-hour individual session 
with exercise physiologist, eight 
online modules
Weekly emails containing health 
information such as health status of 
Australians, PA and nutrition, alcohol 
and tobacco, and mental health.
BBL-GP, Body Brain Life—General Practice; LMP, Lifestyle Modification Programme; PA, physical activity.
Figure 1 Study flow chart. BBL-GP, Body Brain Life—
General Practice; LMP, Lifestyle Modification Programme; PA, 
physical activity.
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an online dementia risk-reduction programme called 
the BBL (trial ID: ACTRN12612000147886)15 44 and the 
Fitness for the Ageing Brain Study (trial ID: ACTRN 
12609000755235).45 46 Contents for the BBL-GP online 
modules have been revised after extensive consumer eval-
uation by members of the Dementia Australia (formally 
known as Alzheimer's Australia) Consumer Dementia 
Research Network as well as members of the public and 
from participant feedback after the previous trial. The 
PA programme has also been modified for a younger 
age group to 18 years and older as previous programmes 
targeted middle aged and older adults. The ActiGraph 
device was introduced to measure the objective amount 
and intensity of PA. This revised programme (Body Brain 
Life—Fit) was piloted with the general public (trial ID: 
ACTRN12615000822583; manuscript in preparation).
Participants in the BBL-GP group are required to 
complete eight modules (dementia literacy, risk factors, 
PA, nutrition, health, cognitive activity, social activity and 
mood) delivered online. Prior to commencing online 
modules, participants in the BBL-GP group also receive 
an individually tailored plan/programme for both dietary 
and PA interventions developed and delivered by a dieti-
tian and an exercise physiologist, respectively, during 
a face-to-face assessment. This is to ensure the dietary 
prescription and level of PA are suitable and tailored to 
individual participants.
PA session
The session duration and frequency of the PA programme 
varies between participants based on baseline PA levels and 
individual tailoring. An exercise physiologist designs an 
individual programme for the participant, delivers this in 
a face-to-face workshop and monitors the PA programme 
via the returned diaries and telephone monitoring. For 
those not doing any regular PA at baseline, the target 
is 150 min/week moderate intensity PA, with moderate 
intensity defined as a score of 10–12 on the Borg Rating 
of Perceived Exertion Scale (RPE).47 For those who are 
doing regular PA but for less than 100 min/week, an addi-
tional 100 min/week is prescribed, and for those meeting 
the target, an additional 50 min/week is prescribed. 
Printed material guiding participants to increase their 
activity level with worksheets is also provided. A diary in 
the format of a calendar returned monthly for 24 weeks 
is used to record PA and RPE to assess PA and intensity 
adherence. Participants may develop a medical problem 
or undergo treatment that can make exercising difficult 
or impossible. If this happens, prescribed amount of exer-
cise is reviewed and represcribed, or stopped.
Dietary session
Participants at baseline who had unintentional weight loss 
of 5 kg or weight gain of 5 kg over the previous 6 months 
were seen by the dietitian. Furthermore, participants, 
whose diets at baseline scored low on one or more of the 
subscales of the ARFS (vegetables<14, fruit<8, protein<4, 
grains<9, dairy <8, water <1),39 were also seen by the 
dietitian. Dietary counselling was provided by a trained 
dietitian and overseen by the coordinating dietitian. 
During the 1-hour face-to-face counselling session, partic-
ipants received individually tailored dietary advice and 
printed material explaining the diet in detail.
Follow-ups
Participants in the BBL-GP group are monitored through 
phone calls at weeks 4, 12 (14 for PA) and week 20 by the 
dietitian and exercise physiologist to monitor the progress 
and for reassurance. In addition, they receive a general 
booster session at 12 months with a phone call and a 
mailed-out booklet summarising materials from the online 
modules. They are being asked to continue being active 
and follow a healthy eating plan after completion of the 
intervention.
Online modules
Once participants in the BBL-GP group have received face-
to-face PA and dietary counselling sessions, they are asked 
to log on to the trial website and complete one module per 
week, each taking approximately 30–40 min. The 12-week 
programme is detailed in table 3. The first 8 weeks include 
the completion of eight educational and individually 
tailored behaviour change modules. In the remaining 4 
weeks, participants undertake online activities focused on 
goal monitoring and revision of the modules materials. 
Tailoring of the six behaviour change modules (weeks 3–8) 
is conducted using an automated algorithm that presents 
content on the basis of whether or not the participant has a 
relevant risk factor, as well as on the basis of their responses 
to several questions measuring psychological determi-
nants of behaviour. These questions are presented at the 
beginning of each of the behaviour change modules. For 
instance, a person who is classified as having a poor diet 
(eg, lack of fish intake) on the basis of their responses on 
the ANU-ADRI, and who does not regard himself/herself 
as a role model to others with respect to their diet habits 
is not presented with information focusing on becoming a 
role model to others.
The programme is built in such a way that participants 
are only able to access the relevant component of the 
intervention at a given time. The modules become active, 
one per week, on the same day for the first 8 weeks. Partic-
ipants are unable to access a newly activated module 
before completing the previously scheduled module. 
Each week, participants receive a notification email on the 
same day of the week alerting them when a new module 
has become active and a list of already activated modules 
that they have either not started or completed. Partici-
pants who are late completing modules will be followed 
up with an email from the project manager to identify 
if there is a reason (eg, holidays, illness, work commit-
ments) preventing their participation, and encouraging 
them to continue with the study. Compliance is recorded 
for each module if they are completed on time, delayed 
or not completed.
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Group 2: Lifestyle Modification Programme (LMP)
The Lifestyle Modification Programme (LMP), developed 
by NHC, is designed to provide individuals with tools to 
help manage chronic disease and maintain a healthy 
lifestyle. LMP is a 6-week group programme provided 
by various health professionals (dietitian, exercise phys-
iologist, nurse practitioner, psychologist, pharmacist 
and sleep physician) providing information on basic 
nutrition, meal planning, PA, health conditions, motiva-
tion and goals, medications and sleep. Every week, two 
sessions are provided on the same day with each session 
lasting an hour. The course is currently run by the NHC 
for their patients to assist them in improving their lifestyle 
and management of chronic disease so it is a pragmatic 
real-life comparison condition. Attendance is recorded 
for compliance and motivation checking. Although the 
LMP is a free nationally recognised programme that is 
designed to provide individuals with tools to help manage 
chronic disease and maintain a healthy lifestyle, evalua-
tion of the programme has not been carried out as yet. 
The attendance is recorded each week to examine inter-
vention fidelity.
Group 3: active control/email only
The active control group or email-only group proceed 
with their normal activities and access health services as 
required over the trial period. Participants in this group 
also receive weekly emails containing links to various 
Table 3 Description of the 12-week online programme delivered through the Body Brain Life —General Practice (BBL-GP) 
website
Week Activity Description
1 Module 1: dementia literacy The first module focuses on providing participants with general information about 
dementia including types, causes, prevalence, social and economic impact, symptoms, 
brain function, treatment, risk factors (modifiable and non-modifiable) and prevention. 
This module serves as an introduction to the subsequent modules.
2 Module 2: dementia risk 
factors
This module is aimed at building awareness and knowledge of the various health 
conditions associated with an increased risk of AD. Specifically, this module provides 
details regarding the association between AD and several medical conditions (abnormal 
weight, high cholesterol, diabetes, hypertension and depression), as well as lifestyle 
factors (alcohol use and smoking, PA, nutrition, stroke and head injury, mental health, 
social and cognitive engagement). The module also briefly covers non-modifiable risk 
factors that contribute to AD, including age and genetics.
3 Module 3: BBL PA This is a theory-driven, individually tailored module that aims to help participants 
incorporate regular PA into their daily routine and reduce sedentary behaviour by 
focusing on increasing endurance, strength, balance and flexibility. This module targets 
several barriers to engaging in PA, such as increasing motivation, creating opportunities 
to exercise and developing a social network that supports PA goals.
4 Module 4: BBL nutrition This is a theory-driven, individually tailored module aimed at helping people develop 
healthy dietary habits. This module targets the risk associated with abnormal weight, and 
the protective effects associated with fish intake and other dietary components.
5 Module 5: BBL health self-
management
This is a theory-driven, individually tailored module aimed at increasing participants’ 
health monitoring and management of chronic health conditions. Because several 
chronic health conditions, such as hypertension, diabetes and high cholesterol, are 
associated with increased risk for dementia, prevention and appropriate management of 
such conditions are also likely to be protective against dementia.
6 Module 6: BBL think—
cognitive engagement
This is a theory-driven, individually tailored module aimed at increasing participants’ 
levels of engagement with mentally stimulating activities such as reading, doing 
crosswords and visiting museums, which is a protective factor against dementia.
7 Module 7: BBL connect—
social engagement
This is a theory-driven, individually tailored module aimed at increasing participants’ 
levels of social engagement. The module targets the risk factor for dementia associated 
with loneliness and the protective effects of regular social engagement.
8 Module 8: BBL mood This is a theory-driven, individually tailored module that aims to help participants 
monitor and maintain good mental health. The module targets risk factors for dementia 
associated with mental health and mood, focusing on depression and anxiety. 
Information is provided on symptoms, types, treatment and tips for managing mood.
9 9–12 Self-guided online 
activities
During these sessions, participants are encouraged to engage in a range of online 
activities for 1 hour, including accessing many tools they have accumulated during the 
first 8 weeks. Examples include the goal-setting tool, behaviour-monitoring tool, unhelpful 
thoughts monitoring tool, videos and so on.
AD, Alzheimer’s disease; PA, physical activity. 
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websites providing information on lifestyle risk factors 
and disease management for a duration of 12 weeks. The 
weekly emails contain several links, and participants are 
encouraged to spend approximately an hour each week 
browsing through the material. The material is generally 
organised around the same themes as the ones included 
in the BBL-GP Programme. An effort has been made to 
include links to relevant information and educational 
material, but that otherwise does not include the use of 
identifiable behaviour-change techniques which are the 
‘active ingredient’ of the BBL-GP Programme. In addi-
tion, other than providing participants with the weekly 
emails, no further contact is made with the participants 
in this group, such as reminders and prompts that are 
provided to the BBL-GP group. Participants in this group 
receive a face-to-face, 1-hour risk-reduction workshop 
that provides the information contained in the BBL-GP 
intervention as a mean of debriefing at the end of the 
intervention.
Masking
To prevent performance bias, research staff conducting 
the assessments remain masked to participants’ group 
allocation. The contact person for participants’ website 
queries, access issues and technical difficulties is inde-
pendent of all baseline assessment data. All participants 
are informed that they are being randomly allocated to 
one of three study groups and that one group may be 
more effective than others. They are also notified at the 
start of the study that one of these groups involves face-
to-face group sessions which require them to travel to 
NHC head office. Hence, the research team members 
who recruit participants, conduct individual diet and 
PA sessions, and professionals who are involved in the 
LMP are naturally able to tell which group they have 
been allocated to. Nurses who conduct baseline and 
follow-up assessments are however masked to group 
allocation.
data management and monitoring
A trial management committee is formed by the research 
team members (chief and co-investigators). Nursing staffs 
from NHC and research assistants collect, clean and send 
the study data to the committee on a weekly basis. Most 
data are automatically entered into excel files and other 
data are double entered to SPSS files to prevent data 
entry errors. Data management is then handled inde-
pendently from the researchers who interpret the data. 
All data are stored electronically and in an independent 
spreadsheet and SPSS data file, which is only accessible by 
the researchers involved in this study.
An independent Data Monitoring Committee (DMC) 
is established independently from the research team who 
are involved with collecting and managing data. The 
DMC provides an independent oversight of the trial and 
reviews general conduct of the trial and study data for 
participant safety. The DMC comprises independent, 
multidisciplinary experts in dementia research who make 
recommendations regarding the continuation, modifica-
tion or termination of the trial.
Adverse events (minor and serious) are monitored 
throughout the trial by the research team and any adverse 
events would be reported to the trial DMC. For this trial, 
an adverse event is defined as an unwanted and usually 
harmful outcome (eg, physical injuries). The event may 
or may not be related to the intervention, but it occurs 
while the person is participating in the intervention, that 
is, while they are undertaking physical activities individu-
ally prescribed by the exercise physiologist.
There are no formal interim analyses planned, as it is 
not expected that adverse events would be differentially 
related to the interventions.
statistical analyses
Statistical analyses will be based on an intention-to-treat 
approach. As applied in the previous BBL project,15 
multiple imputation and mixed models will be applied 
to analyse data. We hypothesise that the effectiveness of 
the intervention programmes will be in the following 
order: BBL-GP>LMP>active control. The hypothesis 
that BBL-GP will be more effective than LMP is based 
on research showing that a tailored programme is 
better than a one size fits all group programme in most 
cases.48 This is also based on the previous BBL project 
where those in BBL groups improved more than those 
in the control group. We will also adjust for compliance 
in completing the online modules and following recom-
mendations provided by the dietitian and exercise physi-
ologist (for BBL-GP group), or for attendance to weekly 
group sessions (for LMP group).
Adverse events
This study evaluates lifestyle intervention programmes 
to reduce risk factors for AD. The target population is 
adults in a primary care setting who have some of the 
known risk factors for dementia, but are at the time of 
the intervention, healthy and free of any dementia-re-
lated symptoms. We do not anticipate that participants 
are placed at a greater risk than that associated with 
self-driven educational activities over the Internet. An 
adverse event where a participant can get hurt during 
prescribed exercise can occur. To prevent this, we screen 
participants using APSS at the baseline assessment to 
identify individuals with acute-risk/high-risk conditions 
for exercise. In addition, the exercise physiologist indi-
vidually tailors prescribed exercise to minimise risk 
of injury. Medical assessments are done by the partici-
pants’ usual nurses and doctors and if any abnormality 
is detected in their results, they are required to discuss 
these abnormalities with participants as usual. To address 
issues of potential fatigue, the assessments have been 
kept to a minimum length. In addition, all online and 
face-to-face sessions are designed in an interactive way 
and are limited to 1-hour sessions (LMP has two themed 
sessions per week and has a break between sessions). As 
mentioned above, all online modules are delivered in an 
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individually tailored fashion to maximise relevance for 
each individual.
dissemination plan
Positive, neutral and negative results of the trial will be 
submitted to international peer-reviewed journals. In 
addition, results will be presented at national and interna-
tional conferences relevant to the subject matters. Author-
ship will be allocated using the guidelines for authorship 
defined by the International Committees of Medical 
Journal Editors and depends on personal involvement.
dIsCussIon
The project is currently under way as an evaluation of 
the efficacy of health promotion interventions in adults 
with risk factors for dementia. The programme aims to 
reduce cardiometabolic risk and promote behaviours 
shown to protect against dementia. The trial, recruiting 
from a primary care setting, has generated considerable 
interest, and to date, approximately half of the total 
target sample has been assessed and randomised into the 
intervention groups. We anticipate that all data collection 
will be completed by December 2018. The results of the 
study are likely to form an evidence base for the feasi-
bility of dementia risk-reduction campaigns to lead to life-
style changes and the reduction of dementia risk factors 
at the population level. This trial will also support the 
feasibility of such interventions being applied in primary 
care settings. Successful outcomes of the current trial may 
lead to significant public health impact and benefits once 
the intervention is made available at the population-level 
pending positive results.
ConClusIon
Interventions to reduce risk of developing dementia are 
needed as a cure is not available. This project compares 
three different approaches to promote healthy lifestyles 
and to reduce risk of developing dementia applied in a 
primary care setting. This unique trial demonstrates real-
life application of dementia risk-reduction intervention 
rather than more controlled but less ecologically valid 
interventions typically tested in a research setting.
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